Key result
Baxdrostat lowers seated systolic BP by ~10 mmHg vs. placebo at 12 weeks.
Why the study?
Poor blood-pressure control and treatment resistance contribute to cardiovascular and kidney complications, with excess aldosterone offering a therapeutic target. This review evaluates the pharmacological profile, clinical efficacy, safety, and regulatory development of baxdrostat, an oral aldosterone synthase inhibitor designed to preserve cortisol production.
Does add-on therapy with the oral aldosterone synthase inhibitor baxdrostat safely and effectively reduce blood pressure in adults with uncontrolled or resistant hypertension?
Does add-on therapy with the oral aldosterone synthase inhibitor baxdrostat safely and effectively reduce blood pressure in adults with uncontrolled or resistant hypertension?
This narrative review synthesizes the clinical evidence supporting the FDA approval of baxdrostat, a selective oral aldosterone synthase inhibitor that significantly lowers office and 24-hour ambulatory blood pressure in uncontrolled and resistant hypertension without suppressing cortisol, though active monitoring for hyperkalaemia and long-term cardiorenal outcome trials are still required.
Answers are grounded in this paper and cite their sources.
May support resistant hypertension therapy with hyperkalemia monitoring; leaves open long-term cardiorenal outcomes.
Introduction: Poor blood-pressure control and treatment resistance contribute to cardiovascular and kidney complications. Excess aldosterone offers a therapeutic target. Objective: This narrative review evaluates the pharmacological profile, clinical efficacy, safety, and regulatory development of baxdrostat, an oral aldosterone synthase inhibitor designed to preserve cortisol production. Key findings: In BaxHTN, a phase 3 trial in uncontrolled or resistant hypertension, the placebo-adjusted decrease in seated systolic blood pressure at week 12 was 8.7 mmHg with 1 mg and 9.8 mmHg with 2 mg; Bax24, a phase 3 ambulatory blood-pressure trial in resistant hypertension, recorded a 14.0 mmHg placebo-adjusted decrease in 24-hour ambulatory systolic pressure with 2 mg. FigHTN, a phase 2 trial in chronic kidney disease, identified a preliminary albuminuria signal, but cardiorenal outcome studies have not yet been completed. The main recognised risks are hyperkalaemia and hyponatraemia, particularly when kidney function is impaired. The United States prescribing information states that safety and effectiveness of initiation at an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2 have not been established, and serum potassium, sodium, and eGFR require surveillance during initiation and dose adjustment. The United States Food and Drug Administration approved baxdrostat (Baxfendy) on May 15, 2026, as an add-on treatment for adults whose hypertension remains inadequately controlled. Concomitant use with a mineralocorticoid receptor antagonist has not been evaluated and should not presently be recommended. Conclusion: Comparative and long-term outcome evidence is still required, while full efficacy and safety results of the completed phase 3 BaxAsia trial in Asian populations are awaited.
No takes yet. Share an insight, caveat, or question.
Rachmawan et al. (2026) conducted a review in Uncontrolled and resistant hypertension (n=796). Baxdrostat vs. Placebo was evaluated on Change in seated systolic blood pressure from baseline to week 12 (BaxHTN pivotal trial, 2 mg dose) (MD -9.8 mmHg, 95% CI -12.6 to -7.0, p=<0.001). Baxdrostat reduced seated systolic BP by a placebo-adjusted 9.8 mmHg in BaxHTN and 24-hour ambulatory systolic BP by 14.0 mmHg in Bax24 at 12 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: